Inicio
Acerca de
¿Qué es el dominio público?
Español
English
Elegir
Autores/as
Obras
Búsqueda avanzada
Género
Cualquiera
Femenino
Masculino
Transmasculino
Transfemenino
No binario
Nacionalidad
Cualquiera
Afganistán
Albania
Argelia
Andorra
Angola
Antigua y Barbuda
Argentina
Armenia
Australia
Austria
Azerbaiyán
Baréin
Bangladés
Barbados
Bielorrusia
Bélgica
Belice
Benín
Bután
Bolivia
Bosnia y Herzegovina
Botsuana
Brasil
Brunéi
Bulgaria
Burkina Faso
Burundi
Camboya
Camerún
Canadá
Cabo Verde
República Centroafricana
Chad
Chile
Colombia
Comoras
Costa Rica
Croacia
Cuba
Chipre
Chequia
República Democrática del Congo
Dinamarca
Yibuti
Dominica
República Dominicana
Timor-Leste
Ecuador
Egipto
El Salvador
Guinea Ecuatorial
Eritrea
Estonia
Esuatini
Etiopía
Islas Feroe
Micronesia
Fiyi
Finlandia
Francia
Gabón
Georgia
Alemania
Ghana
Grecia
Groenlandia
Granada
Guatemala
Guinea
Guinea-Bisáu
Guyana
Haití
Honduras
Hungría
Islandia
India
Indonesia
Irán
Irak
Irlanda
Israel
Italia
Côte d’Ivoire
Jamaica
Japón
Jordania
Kazajistán
Kenia
Kiribati
Kosovo
Kuwait
Kirguistán
Laos
Letonia
Líbano
Lesoto
Liberia
Libia
Liechtenstein
Lituania
Luxemburgo
Madagascar
Malaui
Malasia
Maldivas
Mali
Malta
Islas Marshall
Mauritania
Mauricio
México
Moldavia
Mónaco
Mongolia
Montenegro
Marruecos
Mozambique
Myanmar (Birmania)
Namibia
Nauru
Nepal
Países Bajos
Nueva Zelanda
Nicaragua
Níger
Nigeria
Corea del Norte
Macedonia del Norte
Noruega
Omán
Pakistán
Palaos
Panamá
Papúa Nueva Guinea
Paraguay
China
Perú
Filipinas
Polonia
Portugal
Catar
Congo
Rumanía
Rusia
Ruanda
San Cristóbal y Nieves
Santa Lucía
San Vicente y las Granadinas
Samoa
San Marino
Arabia Saudí
Senegal
Serbia
Seychelles
Sierra Leona
Singapur
Eslovaquia
Eslovenia
Islas Salomón
Somalia
Sudáfrica
Corea del Sur
Sudán del Sur
España
Sri Lanka
Territorios Palestinos
Sudán
Surinam
Suecia
Suiza
Siria
Santo Tomé y Príncipe
Taiwán
Tayikistán
Tanzania
Tailandia
Bahamas
Gambia
Togo
Tonga
Trinidad y Tobago
Túnez
Turquía
Turkmenistán
Tuvalu
Uganda
Ucrania
Emiratos Árabes Unidos
Reino Unido
Estados Unidos
Uruguay
Uzbekistán
Vanuatu
Ciudad del Vaticano
Venezuela
Vietnam
Yemen
Zambia
Zimbabue
Year of death
Cualquiera
Before
In
After
En dominio público
Autores/as cuyas obras están en dominio público en al menos una jurisdicción
Tipo de obra
Cualquiera
Película
Obra literaria
Obra musical
Pintura
Escultura
País de origen
Cualquiera
Afganistán
Albania
Argelia
Andorra
Angola
Antigua y Barbuda
Argentina
Armenia
Australia
Austria
Azerbaiyán
Baréin
Bangladés
Barbados
Bielorrusia
Bélgica
Belice
Benín
Bután
Bolivia
Bosnia y Herzegovina
Botsuana
Brasil
Brunéi
Bulgaria
Burkina Faso
Burundi
Camboya
Camerún
Canadá
Cabo Verde
República Centroafricana
Chad
Chile
Colombia
Comoras
Costa Rica
Croacia
Cuba
Chipre
Chequia
República Democrática del Congo
Dinamarca
Yibuti
Dominica
República Dominicana
Timor-Leste
Ecuador
Egipto
El Salvador
Guinea Ecuatorial
Eritrea
Estonia
Esuatini
Etiopía
Islas Feroe
Micronesia
Fiyi
Finlandia
Francia
Gabón
Georgia
Alemania
Ghana
Grecia
Groenlandia
Granada
Guatemala
Guinea
Guinea-Bisáu
Guyana
Haití
Honduras
Hungría
Islandia
India
Indonesia
Irán
Irak
Irlanda
Israel
Italia
Côte d’Ivoire
Jamaica
Japón
Jordania
Kazajistán
Kenia
Kiribati
Kosovo
Kuwait
Kirguistán
Laos
Letonia
Líbano
Lesoto
Liberia
Libia
Liechtenstein
Lituania
Luxemburgo
Madagascar
Malaui
Malasia
Maldivas
Mali
Malta
Islas Marshall
Mauritania
Mauricio
México
Moldavia
Mónaco
Mongolia
Montenegro
Marruecos
Mozambique
Myanmar (Birmania)
Namibia
Nauru
Nepal
Países Bajos
Nueva Zelanda
Nicaragua
Níger
Nigeria
Corea del Norte
Macedonia del Norte
Noruega
Omán
Pakistán
Palaos
Panamá
Papúa Nueva Guinea
Paraguay
China
Perú
Filipinas
Polonia
Portugal
Catar
Congo
Rumanía
Rusia
Ruanda
San Cristóbal y Nieves
Santa Lucía
San Vicente y las Granadinas
Samoa
San Marino
Arabia Saudí
Senegal
Serbia
Seychelles
Sierra Leona
Singapur
Eslovaquia
Eslovenia
Islas Salomón
Somalia
Sudáfrica
Corea del Sur
Sudán del Sur
España
Sri Lanka
Territorios Palestinos
Sudán
Surinam
Suecia
Suiza
Siria
Santo Tomé y Príncipe
Taiwán
Tayikistán
Tanzania
Tailandia
Bahamas
Gambia
Togo
Tonga
Trinidad y Tobago
Túnez
Turquía
Turkmenistán
Tuvalu
Uganda
Ucrania
Emiratos Árabes Unidos
Reino Unido
Estados Unidos
Uruguay
Uzbekistán
Vanuatu
Ciudad del Vaticano
Venezuela
Vietnam
Yemen
Zambia
Zimbabue
Lista de obras de Matthew D Galbraith
Author response: JAK inhibition decreases the autoimmune burden in Down syndrome
Author response: JAK inhibition decreases the autoimmune burden in Down syndrome
Author response: Seroconversion stages COVID19 into distinct pathophysiological states
Data from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Data from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Data from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Data from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Data from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Data from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Data from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S1 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S1 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S2 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S2 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S3 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S3 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S4 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S4 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S5 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S5 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Figure S6 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
JAK inhibition decreases the autoimmune burden in Down syndrome
JAK inhibition decreases the autoimmune burden in Down syndrome
JAK inhibition decreases the autoimmune burden in Down syndrome
Specialized interferon ligand action in COVID19
Supplemental Figure Legends from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Supplemental Figure Legends from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Supplemental Figures 1-6 from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Supplemental Figures 1-6 from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Supplementary File 1 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 1 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 1 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 1 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 2 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 2 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 2 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 2 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 3 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 3 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 3 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 3 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 4 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 4 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 4 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 4 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 5 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 5 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 5 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 5 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 6 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 6 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 6 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 6 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 7 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 7 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 7 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 7 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 8 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 8 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 8 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary File 8 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Supplementary Methods from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Supplementary Methods from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Supplementary Table 1 from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Supplementary Table 1 from Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Table S1 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Table S1 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Table S2 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Table S2 from SIX2 Mediates Late-Stage Metastasis via Direct Regulation of <i>SOX2</i> and Induction of a Cancer Stem Cell Program
Dominio Público Uruguay cuenta con el apoyo de:
Ártica - Centro Cultural Online
Creative Commons Uruguay
Data Uruguay
Wikimedistas de Uruguay
Acerca de Dominio Público Uruguay
Acerca de
Código fuente
Proyecto Paulina
Ayuda
Documentación